NCT03072160View on ClinicalTrials.gov

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 16, 2017

Primary Completion Date

November 22, 2019

Study Completion Date

November 22, 2019

Conditions
Medullary Thyroid Cancer (MTC)
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03072160 - Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer | Biotech Hunter | Biotech Hunter